Gilbreath M J, Groves J, Pavanand K, Phisphumvithi P
Trans R Soc Trop Med Hyg. 1983;77(6):743-7. doi: 10.1016/0035-9203(83)90277-8.
The anti-malarial drug pyrimethamine suppresses in vitro mitogenic lectin-induced blast transformation by human peripheral blood mononuclear cells (MNC) when the drug is added to cells (1 X 10(-5) M/culture). Sulphadoxine, a second widely used anti-malarial drug has no suppressive effect on the MNC. MNC responsiveness in the mixed leucocyte reaction and cellular viability are not altered by either pyrimethamine or sulphadoxine. In addition, no significant suppression is found when serum obtained from individuals on pyrimethamine-sulphadoxine chemoprophylaxis is added to MNC in the assays. The data, however, do not totally rule out any clinically significant suppressive effect by the anti-malarial drugs on human cellular immune responses.
当将抗疟药物乙胺嘧啶以1×10⁻⁵ M/培养物的浓度添加到细胞中时，它可在体外抑制人外周血单个核细胞（MNC）由有丝分裂原凝集素诱导的母细胞转化。另一种广泛使用的抗疟药物磺胺多辛对MNC没有抑制作用。乙胺嘧啶或磺胺多辛均不会改变混合淋巴细胞反应中的MNC反应性和细胞活力。此外，在检测中，将接受乙胺嘧啶-磺胺多辛化学预防的个体的血清添加到MNC中时，未发现明显的抑制作用。然而，这些数据并未完全排除抗疟药物对人体细胞免疫反应产生任何具有临床意义的抑制作用。
